Evidence Hub

Omalizumab treatment for chronic spontaneous urticaria coinciding with marked improvement of vitiligo: a case report

Lin S, Zhou P, Huang S, Li K, Zhang L

Frontiers in medicine, 2026

Abstract

We report the case of a 49-year-old female patient with a history of hyperthyroidism and long-standing vitiligo for over two decades, who presented with a 6-year history of chronic spontaneous urticaria (CSU) refractory to conventional antihistamine therapy. She was subsequently initiated on subcutaneous omalizumab. This treatment not only led to significant control of her urticaria but also resulted in the unexpected observation of repigmentation of vitiligo lesions on the face and neck. As of the last follow-up in July 2025, the patient remained on omalizumab therapy with sustained improvement in both conditions. This case highlights a potential novel therapeutic effect of omalizumab on vitiligo, warranting further clinical and mechanistic investigation.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free